Your session is about to expire
← Back to Search
Molecular and Structural Imaging for Alzheimer's Disease
N/A
Recruiting
Led By Jennifer Whitwell, Ph.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA)
Must not have
Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
Women that are pregnant or post-partum and breast-feeding will be excluded
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at amyloid and tau in the brains of people with atypical Alzheimer's to see how it changes over time.
Who is the study for?
This study is for adults over 21 with Atypical Alzheimer's Disease, specifically those diagnosed with Logopenic Aphasia or Posterior Cortical Atrophy. Participants must have a person to report on their functioning and speak English as their primary language. They can't join if they've had strokes, tumors, severe memory issues early on, other neurodegenerative diseases, very poor vision, are pregnant/breastfeeding, or have MRI contraindications.
What is being tested?
The trial is using advanced brain imaging techniques (F-18 AV 1451 and C-11 PiB) to investigate the presence of amyloid and tau proteins in patients' brains. It aims to see how these protein levels change over one year in individuals with atypical forms of Alzheimer's disease.
What are the potential side effects?
While the document doesn’t specify side effects related to F-18 AV 1451 and C-11 PiB imaging agents used in PET scans directly, common side effects from such procedures may include discomfort at injection site or allergic reactions; however individual experiences may vary.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have trouble finding the right words and forming sentences.
Select...
I have Alzheimer's with worsening memory loss or specific symptoms like LPA or PCA.
Select...
I am over 21 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any other neurodegenerative disorders like frontotemporal dementia.
Select...
I am not pregnant, post-partum, or breastfeeding.
Select...
I can have a tau-PET scan and don't have Cowden, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich, or Down's syndrome.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment2 Interventions
All subjects will receive two Tau PET scans during this study.
Group II: PiB PET Scan, C-11 PiBExperimental Treatment2 Interventions
All subjects will receive two PiB PET scans during this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
C-11 PiB
2010
Completed Phase 1
~240
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,360 Previous Clinical Trials
3,065,881 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,802 Previous Clinical Trials
28,193,921 Total Patients Enrolled
Jennifer Whitwell, Ph.D.Principal Investigator - Mayo Clinic
Mayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have any other neurodegenerative disorders like frontotemporal dementia.I have had a stroke or tumor that might be causing my symptoms.I have trouble finding the right words and forming sentences.I am not pregnant, post-partum, or breastfeeding.I have Alzheimer's with worsening memory loss or specific symptoms like LPA or PCA.I can have a tau-PET scan and don't have Cowden, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich, or Down's syndrome.My memory loss affects things other than recalling personal experiences.I am over 21 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Tau PET Scan, F-18 AV 1451
- Group 2: PiB PET Scan, C-11 PiB
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.